Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Immunol ; 158(1): 29-34, 2015 May.
Article in English | MEDLINE | ID: mdl-25762520

ABSTRACT

Newborn screening (NBS) for severe combined immunodeficiency (SCID) identifies affected infants before the onset of life-threatening infections, permitting optimal treatment. Navajo Native Americans have a founder mutation in the DNA repair enzyme Artemis, resulting in frequent Artemis SCID (SCID-A). A pilot study at 2 Navajo hospitals assessed the feasibility of SCID NBS in this population. Dried blood spots from 1800 infants were assayed by PCR for T-cell receptor excision circles (TRECs), a biomarker for naïve T cells. Starting in February 2012, TREC testing transitioned to standard care throughout the Navajo Area Indian Health Service, and a total of 7900 infants were screened through July 2014. One infant had low TRECs and was diagnosed with non-SCID T lymphopenia, while 4 had undetectable TRECs due to SCID-A, all of whom were referred for hematopoietic cell transplantation. This report establishes the incidence of SCID-A and demonstrates effectiveness of TREC NBS in the Navajo.


Subject(s)
Indians, North American/genetics , Lymphopenia/diagnosis , Nuclear Proteins/genetics , Severe Combined Immunodeficiency/diagnosis , DNA-Binding Proteins , Endonucleases , Feasibility Studies , Humans , Infant, Newborn , Lymphopenia/genetics , Neonatal Screening , Pilot Projects , Polymerase Chain Reaction , Severe Combined Immunodeficiency/genetics
2.
J Clin Immunol ; 33(3): 540-9, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23264026

ABSTRACT

PURPOSE: Severe combined immunodeficiency (SCID) is characterized by failure of T lymphocyte development and absent or very low T cell receptor excision circles (TRECs), DNA byproducts of T cell maturation. Newborn screening for TRECs to identify SCID is now performed in several states using PCR of DNA from universally collected dried blood spots (DBS). In addition to infants with typical SCID, TREC screening identifies infants with T lymphocytopenia who appear healthy and in whom a SCID diagnosis cannot be confirmed. Deep sequencing was employed to find causes of T lymphocytopenia in such infants. METHODS: Whole exome sequencing and analysis were performed in infants and their parents. Upon finding deleterious mutations in the ataxia telangiectasia mutated (ATM) gene, we confirmed the diagnosis of ataxia telangiectasia (AT) in two infants and then tested archival newborn DBS of additional AT patients for TREC copy number. RESULTS: Exome sequencing and analysis led to 2 unsuspected gene diagnoses of AT. Of 13 older AT patients for whom newborn DBS had been stored, 7 samples tested positive for SCID under the criteria of California's newborn screening program. AT children with low neonatal TRECs had low CD4 T cell counts subsequently detected (R = 0.64). CONCLUSIONS: T lymphocytopenia in newborns can be a feature of AT, as revealed by TREC screening and exome sequencing. Although there is no current cure for the progressive neurological impairment of AT, early detection permits avoidance of infectious complications, while providing information for families regarding reproductive recurrence risks and increased cancer risks in patients and carriers.


Subject(s)
Ataxia Telangiectasia/diagnosis , Neonatal Screening , Severe Combined Immunodeficiency/diagnosis , Amino Acid Sequence , Ataxia Telangiectasia/complications , Ataxia Telangiectasia/genetics , Ataxia Telangiectasia Mutated Proteins , Base Sequence , Cell Cycle Proteins/genetics , Child , Child, Preschool , DNA-Binding Proteins/genetics , Exome , Female , Humans , Infant , Infant, Newborn , Lymphopenia/genetics , Male , Mutation , Phenotype , Polymorphism, Single Nucleotide , Protein Serine-Threonine Kinases/genetics , Severe Combined Immunodeficiency/complications , Severe Combined Immunodeficiency/genetics , Tumor Suppressor Proteins/genetics
3.
Mol Genet Metab ; 107(3): 586-91, 2012 Nov.
Article in English | MEDLINE | ID: mdl-23062576

ABSTRACT

T-cell receptor excision circles (TRECs) are circular DNA molecules formed during rearrangement of the T-cell receptor (TCR) genes during lymphocyte development. Copy number of the junctional portion of the δRec-ψJα TREC, assessed by quantitative PCR (qPCR) using DNA from dried blood spots (DBS), is a biomarker for newly formed T cells and absent or low numbers of TRECs indicate SCID (severe combined immunodeficiency) or T lymphocytopenia. No quantitation standard for TRECs exists. To permit comparison of TREC qPCR results with a reliable method for counting TRECs across different laboratories, we sought to construct a stable cell line containing a normal human chromosomal constitution and a single copy of the TREC junction sequence. A human EBV (Epstein Barr virus)-transformed B-cell line was transduced with a lentivirus encoding mCherry fluorescence, puromycin resistance and the δRec-ψJα TREC sequence. A TREC-EBV cell line, with each cell carrying a single lentiviral insertion was established, expanded and shown to have one TREC copy per diploid genome. Graded numbers of TREC-EBV cells added to aliquots of T lymphocyte depleted blood showed TREC copy number proportional to TREC-EBV cell number. TREC-EBV cells, therefore, constitute a reproducible cellular calibrator for TREC assays, useful for both population-based screening for severe combined immunodeficiency and evaluation of naïve T-cell production in clinical settings.


Subject(s)
DNA, Circular/analysis , Receptors, Antigen, T-Cell/genetics , T-Lymphocytes/pathology , B-Lymphocytes/metabolism , Biomarkers/analysis , Cell Line, Transformed , DNA Copy Number Variations , Dried Blood Spot Testing , Gene Rearrangement, T-Lymphocyte , Genes, Reporter , Genetic Vectors , Herpesvirus 4, Human/genetics , Humans , Infant, Newborn , Lentivirus/genetics , Lymphocyte Count , Lymphopenia/diagnosis , Lymphopenia/genetics , Lymphopenia/pathology , Neonatal Screening , Polymerase Chain Reaction , Severe Combined Immunodeficiency/diagnosis , Severe Combined Immunodeficiency/genetics , Severe Combined Immunodeficiency/pathology , T-Lymphocytes/metabolism
4.
J Immunol ; 189(3): 1253-64, 2012 Aug 01.
Article in English | MEDLINE | ID: mdl-22753936

ABSTRACT

Absent T lymphocytes were unexpectedly found in homozygotes of a transgenic mouse from an unrelated project. T cell development did not progress beyond double-negative stage 1 thymocytes, resulting in a hypocellular, vestigial thymus. B cells were present, but NK cell number and B cell isotype switching were reduced. Transplantation of wild-type hematopoietic cells corrected the defect, which was traced to a deletion involving five contiguous genes at the transgene insertion site on chromosome 12C3. Complementation using bacterial artificial chromosome transgenesis implicated zinc finger BTB-POZ domain protein 1 (Zbtb1) in the immunodeficiency, confirming its role in T cell development and suggesting involvement in B and NK cell differentiation. Targeted disruption of Zbtb1 recapitulated the T(-)B(+)NK(-) SCID phenotype of the original transgenic animal. Knockouts for Zbtb1 had expanded populations of bone marrow hematopoietic stem cells and also multipotent and early lymphoid lineages, suggesting a differentiation bottleneck for common lymphoid progenitors. Expression of mRNA encoding Zbtb1, a predicted transcription repressor, was greatest in hematopoietic stem cells, thymocytes, and pre-B cells, highlighting its essential role in lymphoid development.


Subject(s)
Cell Differentiation/immunology , Lymphocyte Subsets/cytology , Lymphocyte Subsets/immunology , Repressor Proteins/physiology , Zinc Fingers/immunology , Animals , Cell Differentiation/genetics , Hematopoietic Stem Cells/cytology , Hematopoietic Stem Cells/immunology , Hematopoietic Stem Cells/metabolism , Lymphocyte Subsets/metabolism , Mice , Mice, Inbred C57BL , Mice, Knockout , Mice, SCID , Mice, Transgenic , NIH 3T3 Cells , Precursor Cells, B-Lymphoid/cytology , Precursor Cells, B-Lymphoid/immunology , Precursor Cells, B-Lymphoid/metabolism , Precursor Cells, T-Lymphoid/cytology , Precursor Cells, T-Lymphoid/immunology , Precursor Cells, T-Lymphoid/metabolism , RNA, Messenger/biosynthesis , Repressor Proteins/deficiency , Repressor Proteins/genetics
5.
Endocrine ; 32(2): 129-35, 2007 Oct.
Article in English | MEDLINE | ID: mdl-18008187

ABSTRACT

Astrocytomas are the most frequent primary brain tumors and constitute a leading cause of cancer-related deaths. We studied the effects of progesterone and its antagonist, RU486, on cell growth of two human astrocytoma cell lines with different evolution grade (U373, grade III; and D54, grade IV). Progesterone receptor expression was determined by Western blot. The effects of different doses of progesterone and RU486 on cell number, cell cycle, and apoptosis were analyzed for five consecutive days. Progesterone (10 nM) significantly increased the number of D54 cells from the second day of culture, and the number of U373 cells on days 3-5. RU486 (10 muM) blocked progesterone effects in both astrocytoma cell lines. Interestingly, RU486 administered without progesterone significantly reduced the number of cells from the second day of culture in both cell lines. Progesterone increased S phase of cell cycle in U373 cells (61%, on day 5). RU486 blocked the effects of progesterone on cell cycle but administered alone did not significantly change cell cycle profile. DNA fragmentation (TUNEL) assay showed that the diminution in the number of astrocytoma cells produced by RU486 was not by apoptosis. Progesterone receptor isoforms were detected in both cell lines. Our data suggest that progesterone induces cell growth of human astrocytoma cell lines through the interaction with its nuclear receptor.


Subject(s)
Astrocytoma/pathology , Brain Neoplasms/pathology , Cell Proliferation/drug effects , Progesterone/pharmacology , Progestins/pharmacology , Apoptosis/drug effects , Astrocytoma/metabolism , Brain Neoplasms/metabolism , Cell Cycle/drug effects , Cell Line, Tumor , Hormone Antagonists/pharmacology , Humans , Mifepristone/pharmacology , Progesterone/metabolism
6.
Int Wound J ; 4(3): 241-50, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17924880

ABSTRACT

For the past 20 years, super-oxidised solutions (SOSs) have been shown to be potent antimicrobials and disinfectants via oxidative damage. However, the potential toxicity of SOSs on eukaryotic cells has not been documented in vitro. This is relevant because oxygen and chlorine reactive species may possibly induce ageing and irreversible cellular dysfunctions that eventually produce cell death. The present study investigates the cytotoxicity and oxidative stress induced by a novel, pH-neutral SOS (i.e. Microcyn, MCN) on young, primary diploid - human dermal fibroblast (HDF) cultures. For this purpose, hydrogen peroxide (HP) was used as a positive control of oxidative damage. When these solutions were used at concentrations indicated for wound care (i.e. undiluted MCN or 880 mM HP), HP was significantly more toxic than MCN. After 5 and 30 minutes of exposure, cell viability was 38% and 5%, respectively, in 880 mM HP-treated cells versus 75% and 70% in MCN-treated populations, respectively. HP induced both apoptosis and necrosis, whereas MCN induced only necrosis. Genotoxic and ageing studies were then conducted at sublethal HP concentrations as previously reported in the literature. Cellular DNA and RNA were partially degraded only in HDFs exposed to 500 microM HP for 30 minutes but not in those exposed to undiluted MCN. At this same concentration, HP induced the formation of 8-hydroxy-2'deoxyguanosine adducts in HDFs but this effect was neither observed in control- nor observed in MCN-treated cells. HDFs were further exposed to 5 microM HP or 10% MCN for 1 month. The expression of senescence-associated-beta-galactosidase was only significantly elevated in cells chronically exposed to 5 microM HP. Altogether, these results show that MCN is significantly less cytotoxic than antiseptic HP concentrations (i.e. 880 mM) and that, in vitro, it does not induce genotoxicity or accelerated ageing.


Subject(s)
Disinfectants/pharmacology , Fibroblasts/drug effects , Fibroblasts/pathology , Hydrogen Peroxide/pharmacology , Skin/cytology , 8-Hydroxy-2'-Deoxyguanosine , Anti-Infective Agents, Local/pharmacology , Apoptosis/drug effects , Cell Survival/drug effects , Cells, Cultured , DNA Adducts/drug effects , DNA Damage/drug effects , Deoxyguanosine/analogs & derivatives , Deoxyguanosine/metabolism , Humans , Hydrogen-Ion Concentration , Necrosis/chemically induced , Oxidative Stress/drug effects , RNA Stability/drug effects , beta-Galactosidase/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...